Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and ...
EMA validates Immunome’s MAA for varegacestat, an oral, once-daily gamma secretase inhibitor to treat adults with desmoid tumours: Bothell, Washington Monday, November 2, 2026, ...
Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer ...
For patients with desmoid tumors, treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome.
Immunome, Inc. (Nasdaq: IMNM) announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for varegacestat, an investigational oral once-daily gamma ...
Explore PBLS’s desmoid tumor potential, PEDESTAL Phase 3 progress, Wnt-driven oncology upside, and why this speculative ...
Immunome, Inc. had the European Medicines Agency validate the Marketing Authorization Application for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor for the treatment of ...
A preclinical study reports that the EGFR inhibitor osimertinib and the XPO1 inhibitor selinexor synergistically deplete ...
Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week ...
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically ...
Parabilis Medicines, Inc. is rated a speculative Buy due to its innovative peptide platform and strong rare-disease oncology ...
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results